Oncothyreon has developed PET-Lipid A, a fully synthetic, patent protected vaccine adjuvant. PET-Lipid A interacts with a cell surface receptor (TLR4) that is known to play an important role in activating innate immunity and regulating the productions of cytokines (proteins that control immune cell activity).
In preclinical studies evaluating immune stimulation, PET-Lipid A is more than 10 times more potent than MPL®, a TLR4 adjuvant that is a component of commercial vaccines as well as tecemotide [View Poster]. Unlike MPL, a natural product derived from the bacterium Salmonella minnesota, PET-Lipid A is fully synthetic. Use of synthetic manufacturing processes helps to eliminate lot-to-lot variability that can occur with natural products, allows better quality control and reduces the costs of production.
PET-Lipid A is a component of ONT-10, a therapeutic vaccine that Oncothyreon is developing for the treatment of cancers that express MUC1.
Oncothyreon has comprehensive intellectual property protection around PET-Lipid A.